Clinical trials: Metastatic Colorectal Cancer (MCRC)
Metastatic Colorectal Cancer
Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).
This is a Phase IV, single-arm, prospective, open-label, multicenter, interventional study to evaluate safety and efficacy of regorafenib in patients with mCRC who have been previously treated with fluoropyrimidine …
- Trial name
- NCT03564938
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- 13 sites in India
- Volunteers
- 100 people
- Sponsor
- Bayer
Metastatic Colorectal Cancer
Sulfasalazine in Patients With Metastatic Colorectal Cancer
The aim of this study is to evaluate the potential efficacy and safety of sulfasalazine in patients with metastatic colorectal cancer.
- Trial name
- NCT06134388
- Testing
- Sulfasalazine
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Tanta University
CRC
Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC
This is An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 (Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection) + HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody…
- Trial name
- NCT05239650
- Testing
- HLX07, HLX10, mFOLFOX6
- Volunteers
- 50 people
- Sponsor
- Shanghai Henlius Biotech
Metastatic Colorectal Cancer
CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer
HS-CA102N-103 is a Phase 2, randomized, open label study to evaluate efficacy, safety, and tolerability of CA102N combined with trifluridine/tipiracil (TAS-102) compared to bevacizumab combined with TAS-102 in subjects with…
- Trial name
- NCT06039202
- Testing
- CA102N, TAS-102, Bevacizumab
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Holy Stone Healthcare Co., Ltd
Metastatic Colorectal Cancer, KRAS Gene Mutation
Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer
This is an expanded access program for eligible participants designed to provide access to onvansertib in combination with FOLFIRI and bevacizumab.
- Trial name
- NCT04446793
- Testing
- Onvansertib, Bevacizumab, FOLFIRI
- Sponsor
- Cardiff Oncology
Fruquintinib, Metastatic Colorectal Cancer
Fruquintinib in the Cross-line Treatment of Refractory mCRC
This is a real-world study. Patients with metastatic colorectal cancer who have progressed (PD) after third-line treatment with fruquintinib combined with PD-1 inhibitors will receive fruquintinib combined with TAS-102 as…
- Trial name
- NCT06099314
- Testing
- Fruquintinib+PD-1 inhibitors, Fruquintinib+TAS-102
- Where
- 3 sites in China
- Volunteers
- 36 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Metastatic Colorectal Cancer, Colorectal Cancer Metastatic
Sym004 Versus Futuximab or Modotuximab in Patients With mCRC
This is a Phase 2, randomized, open-label, 3-arm trial in the ratio of 1:1:1 to either Sym004 (Arm A) versus each of its component monoclonal antibodies (mAbs), futuximab (Arm B) or modotuximab (Arm C), in genomically-selected…
- Conditions
- Metastatic Colorectal Cancer, Colorectal Cancer Metastatic, Carcinoma
- Trial name
- NCT03549338
- Testing
- Sym004, Futuximab, Modotuximab
- Where
- 18 sites in United States, Germany and 2 more
- Volunteers
- 2 people
- Sponsor
- Symphogen A/S
Colon Cancer Liver Metastasis
Safety of TACE With Oxaliplatin, Irinotecan and Raltitrexed for Refractory Colorectal Cancer Liver Metastasis
The purpose of this study is to observe whether hepatic infusion by oxaliplatin, irinotecan and raltitrexed with or without embolization by lipiodol or microspheres are effective in the treatment of refratory liver metastasis…
- Trial name
- NCT02631564
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fudan University
Metastatic Colorectal Cancer
Escalated Dose of Irinotecan in mCRC
Metastatic diseases were found in 20-25% of patients with initial diagnosis of colorectal cancer and developed in up to 50% of patients.
- Trial name
- NCT02256800
- Testing
- UGT1A1 genotyping (6,6), UGTIA1 genotyping (6,7), UGTIA1 genotyping (7,7)
- Where
- Taiwan
- Volunteers
- 213 people
- Sponsor
- Jaw-Yuan Wang, MD, PhD
Advanced Malignant Solid Neoplasm, Advanced Biliary Tract Carcinoma
Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer
This phase II trial tests how well olanzapine works in managing cancer cachexia in patients experiencing esophagogastric, hepatopancreaticobiliary, colorectal, or lung cancer that may have spread from where it first started to…
- Conditions
- Advanced Malignant Solid Neoplasm, Advanced Biliary Tract Carcinoma, Advanced Esophageal Carcinoma, Metastatic Esophageal Carcinoma
- Trial name
- NCT05705492
- Testing
- Olanzapine, Questionnaire Administration
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- OHSU Knight Cancer Institute
Metastatic Colorectal Cancer
Detection of the Emergence of RAS (Rat Sarcoma Viral Oncogene Homolog) Mutations in Circulating DNA (Deoxyribonucleic Acid) in Patients With mCRC (Metastatic Colorectal Cancer) During Treatment With Anti-EGFR (Epidermal Growth Factor Receptor) Therapy
The analysis of circulating DNA (Deoxyribonucleic acid) to identify potential resistance mechanisms during anti-EGFR (epidermal growth factor receptor) treatment is of great interest, as evidenced by the recent journal published…
- Trial name
- EmutRAS (NCT03908788)
- Testing
- Intplex test
- Where
- 2 sites in France
- Volunteers
- 130 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Unresectable Metastatic Colorectal Cancer
mXELOXIRI Combined With Molecular Targeted Drug in mCRC
The objective is to evaluate the efficacy and safety of modified XELOXIRI combined with molecular targeted drug as first-line therapy in patients with metastatic colorectal cancer (mCRC)
- Trial name
- TRICAP (NCT04160416)
- Testing
- Capecitabine-Oxaliplatin-Irinotecan Combination
- Where
- China
- Volunteers
- 48 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Metastatic Colorectal Cancer, Metastatic Colon Cancer
A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer
This is a global, randomized, double-blind, placebo-controlled, multicenter phase 3 clinical trial to compare the efficacy and safety of fruquintinib plus best supportive care (BSC) versus placebo plus BSC in participants with…
- Trial name
- FRESCO-2 (NCT04322539)
- Testing
- Fruquintinib
- Where
- 153 sites in United States, Australia and 12 more
- Volunteers
- 691 people
- Sponsor
- Hutchison Medipharma Limited
Colorectal Neoplasms Malignant
Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC
This was a single-arm, prospective study to investigate the safety of cetuximab in combination with trifluridin tipiracil (TAS-102) in the third-line treatment of Chinese patients with RAS wild-type mCRC.
- Trial name
- NCT05155124
- Testing
- Cetuximab + trifluridin tipiracil
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Colorectal Neoplasms, Metastatic Disease
Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer
The purpose of this study is to assess the efficacy and safety of single-agent regorafenib in the first line treatment of frail and/or unfit for polychemotherapy patients with metastatic colorectal cancer (mCRC)
- Trial name
- REFRAME (NCT01875380)
- Testing
- Regorafenib
- Where
- Spain
- Volunteers
- 46 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Colorectal Carcinoma
Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy
The purpose of this study is to determine safety and local tumor control of Embozene TANDEM Microspheres (40um TANDEM) loaded with Irinotecan to treat metastatic colorectal carcinoma (mCRC).
- Trial name
- MIRACLEIII (NCT02694562)
- Testing
- 40um Embozene TANDEM Microspheres
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- Boston Scientific Corporation
CRC (Colorectal Cancer)
Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC
The EpiDRIVE study aims to identify cfDNA-based epigenetic determinants of response in metastatic colorectal cancer (mCRC) patients treated with EGFR- or VEGF-targeted therapy.
- Trial name
- EpiDRIVE (NCT07224841)
- Testing
- cfDNA 5mC/5hmC Sequencing (EpiDRIVE Discovery Phase), EpiDRIVE Assay (Targeted Sequencing / qPCR Validation)
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- City of Hope Medical Center
Circulating Tumor DNA
The Value of ctDNA on Chemotherapy Efficacy for mCRC
The study is designed to evaluate the value of ctDNA in predicting the drug efficacy of chemotherapy for metastatic colorectal cancer.
- Trial name
- NCT04555369
- Testing
- ct-DNA
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Fudan University
Metastatic Colorectal Cancer
Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients
This is a Phase Ib study to evaluate the safety and preliminary anti-tumor activity of pembrolizumab in combination with pemetrexed with or without oxaliplatin in patients with chemo-refractory microsatellite stable (MSS)…
- Trial name
- NCT03626922
- Testing
- Pembrolizumab, Pemetrexed, Oxaliplatin
- Where
- 15 sites in United States
- Volunteers
- 33 people
- Sponsor
- NSABP Foundation Inc
Synchronous Isolated Para-aortic Lymph Node Metastasis, Colorectal Cancer
Systemic Therapy Sequenced Isolated PALND for mCRC
The study aims to estimate the efficacy and safety of systemic therapy sequenced radical surgery in treating patients with synchronous isolated para-aortic lymph node metastasis of colorectal cancer.
- Trial name
- NCT04774757
- Testing
- Para-aortic lymph node dissection
- Where
- China
- Volunteers
- 39 people
- Sponsor
- First Affiliated Hospital of Zhejiang University